Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development

References 

1. DeFazio J, Meldrum DR, Lu JK, Vale WW, Rivier JE, Judd HL, et al. Acute ovarian responses to a long-acting agonist of gonadotropin-releasing hormone in ovulatory women and women with polycystic ovarian disease. Fertil Steril. 1985;44:453–459
   • MEDLINE
2. Garcia JE, Padilla SL, Bayati J, Baramki TA. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. Fertil Steril. 1990;53:302–305
   • MEDLINE
3. Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril. 1994;61:880–885
   • MEDLINE
4. Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril. 1997;67:93–97
   • Abstract
   • Full-Text PDF (417 KB)
   • CrossRef
5. Jones PBC. Potential relevance of gonadotropin-releasing hormone to ovarian physiology. Semin Reprod Endocrinol. 1989;7:41–51
6. Padilla SL, Dugan K, Maruschak V, Shalika S, Smith RD. Use of the flare-up protocol with high dose human follicle-stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. Fertil Steril. 1996;65:796–799
   • MEDLINE
7. Scott RT. Evaluation and treatment of low responders. Semin Reprod Endocrinol. 1996;14:317–337
   • MEDLINE
8. Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril. 2000;73:667–676
   • Abstract
   • Full Text
   • Full-Text PDF (192 KB)
   • CrossRef
9. Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril. 1998;69:419–424
   • Abstract
   • Full Text
   • Full-Text PDF (93 KB)
   • CrossRef
10. Saadat P, Slater C, Jain J, Tourgeman D, Stanczyk F, Paulson R. Treatment-associated serum FSH levels in very poor responders to ovarian stimulation. J Assist Reprod Genet. 2003;20:395–399
11. Scott RT, Carey KD, Leland M, Navot D. Gonadotropin responsiveness to ultralow-dose leuprolide acetate administration in baboons. Fertil Steril. 1993;59:1124–1128
    • MEDLINE
12. Baird DT. A model for follicular selection and ovulation: lessons from superovulation. J Steroid Biochem. 1987;27:15–23
    • MEDLINE
    • CrossRef
13. Hodgen GD. The dominant ovarian follicle. Fertil Steril. 1982;38:281–300
    • MEDLINE
14. Brown JB. Pituitary control of ovarian function: concepts derived from gonadotropin therapy. Aust NZ J Obstet Gynaecol. 1978;18:47–54
15. Messinis IE, Templeton AA. The importance of follicle-stimulating hormone increase for folliculogenesis. Hum Reprod. 1990;5:153–156
    • MEDLINE
16. Schipper I, Hop WCJ, Fauser BCJM. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development. J Clin Endocrinol Metab. 1998;83:1292–1298
    • CrossRef
17. Meldrum DR, Tsao Z, Munroe SE, Braunstein GD, Sladek J, Lu JK, et al. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J Clin Endocrinol Metab. 1984;58:755–757
    • CrossRef
18. Monroe SE, Blumenfeld Z, Andreyko JL, Schriock E, Henzl MR, Jaffe RB. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin). J Clin Endocrinol Metab. 1986;63:1334–1341
    • CrossRef